Cargando…

Prostate cancer and hypofractionation: really a new standard of care?

Detalles Bibliográficos
Autores principales:	Carrie, Christian, Tanguy, Ronan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2016
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5182230/ https://www.ncbi.nlm.nih.gov/pubmed/28078233 http://dx.doi.org/10.21037/tau.2016.08.19

Ejemplares similares

Moderate hypofractionation for prostate cancer
por: Arcangeli, Stefano, et al.
Publicado: (2017)

Hypofractionation trials and radiobiology of prostate cancer
por: Gulliford, Sarah, et al.
Publicado: (2017)

Standard Versus Hypofractionated Radiation Therapy for Bladder Cancer: New Insights, but Questions Remain
por: Baumann, Brian C., et al.
Publicado: (2021)

Combined-modality hypofractionated radiotherapy for elderly patients with glioblastoma: setting a new standard
por: Vellayappan, Balamurugan A, et al.
Publicado: (2017)

Are we ready to use hypofractionated instead of conventional radiotherapy for prostate cancer? Not yet
Publicado: (2019)

Hypofractionated radiotherapy for prostate cancer
por: Hegemann, Nina-Sophie, et al.
Publicado: (2014)

Moderate hypofractionation for prostate cancer
por: Lee, W. Robert, et al.
Publicado: (2018)

Vestibular Schwannoma: Results of Hypofractionated Stereotactic Radiation Therapy
por: Pialat, Pierre-Marie, et al.
Publicado: (2021)

Thyroid Prostate Axis. Does It Really Exist?
por: La Vignera, Sandro, et al.
Publicado: (2019)

Review of Hypofractionated Radiotherapy for Prostate Cancer
por: Spyropoulou, Despina, et al.
Publicado: (2012)

The Role of Hypofractionated Radiotherapy in Prostate Cancer
por: Benjamin, Linus C., et al.
Publicado: (2017)

Brain metastases treated with hypofractionated stereotactic radiotherapy: 8 years experience after Cyberknife installation
por: Mengue, Laurence, et al.
Publicado: (2020)

Local therapy in patients with metastatic prostate cancer: a new standard of care?
por: Harper, Benjamin, et al.
Publicado: (2019)

Perilesional sampling: the new standard for imaging-targeted prostate biopsies?
por: Thomas, Christian
Publicado: (2023)

Hypofractionated External-Beam Radiotherapy for Prostate Cancer
por: Cho, L. Chinsoo, et al.
Publicado: (2013)

Extreme Hypofractionation with SBRT in Localized Prostate Cancer
por: Gómez-Aparicio, Maria Antonia, et al.
Publicado: (2021)

Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?
por: Negri, Francesca, et al.
Publicado: (2021)

Metastasis-directed therapy: a new standard for oligorecurrent prostate cancer?
por: Zilli, Thomas, et al.
Publicado: (2018)

Evaluating Thresholds to Adopt Hypofractionated Preoperative Radiotherapy as Standard of Care in Sarcoma
por: Valle, Luca F., et al.
Publicado: (2021)

Hypofractionation in Prostate Cancer: Radiobiological Basis and Clinical Appliance
por: Mangoni, M., et al.
Publicado: (2014)

Better Care Through Hypofractionation
por: Boisvert-Huneault, Christian, et al.
Publicado: (2022)

Intrafraction Prostate Motion Management for Ultra-Hypofractionated Radiotherapy of Prostate Cancer
por: Oehler, Christoph, et al.
Publicado: (2022)

When Less is More: The Rising Tide of Hypofractionation
por: Aitken, K., et al.
Publicado: (2022)

Is moderate hypofractionation accepted as a new standard of care in north america for prostate cancer patients treated with external beam radiotherapy? Survey of genitourinary expert radiation oncologists
por: McClelland, Shearwood, et al.
Publicado: (2019)

Hypofractionation: The standard for external beam breast irradiation
por: Brunt, Adrian Murray, et al.
Publicado: (2023)

Acute toxicities after extremely hypofractionated radiotherapy for prostate cancer: lessons from HYPO-RT-PC and PACE-B
por: Juarez, Jesus E., et al.
Publicado: (2020)

PO-1181 Hypofractionation in NSCLC as the new standard of care during SARS-CoV-2 pandemia.
por: Vera Barragán, V., et al.
Publicado: (2021)

Infliximab, Is It Really a New Horizon for the Treatment of Kawasaki Disease?
por: Eun, Lucy Youngmin
Publicado: (2019)

Acute toxicity profile in prostate cancer with conventional and hypofractionated treatment
por: Viani, Gustavo Arruda, et al.
Publicado: (2013)

Evolution of Hypofractionated Accelerated Radiotherapy for Prostate Cancer – The Sunnybrook Experience
por: Musunuru, Hima Bindu, et al.
Publicado: (2014)

Investigating the Benefit of Combined Androgen Modulation and Hypofractionation in Prostate Cancer
por: Zamagni, Alice, et al.
Publicado: (2020)

Hypofractionated Postoperative Radiotherapy for Prostate Cancer: Is the Field Ready Yet?
por: Mahase, Sean, et al.
Publicado: (2020)

Practical Guidelines on Implementing Hypofractionated Radiotherapy for Prostate Cancer in Africa
por: Swanson, William, et al.
Publicado: (2021)

Hypofractionation Adoption in Prostate Cancer Radiotherapy: Results of an International Survey
por: Sabbagh, Ali, et al.
Publicado: (2023)

Practical considerations for prostate hypofractionation in the developing world
por: Yan, Michael, et al.
Publicado: (2021)

Hyperglycemia and COVID-19: What was known and what is really new?
por: Ceriello, Antonio
Publicado: (2020)

1-week hypofractionated adjuvant whole-breast radiotherapy: towards a new standard?
por: Levy, Antonin, et al.
Publicado: (2020)

Benefits of Adopting Hypofractionated Radiotherapy as a Standard of Care in Low-and Middle-Income Countries
por: Kraus, Ryan D., et al.
Publicado: (2022)

Long-term results of a phase II study of hypofractionated proton therapy for prostate cancer: moderate versus extreme hypofractionation
por: Ha, Boram, et al.
Publicado: (2019)

Extreme hypofractionation in radiation therapy for patients with early breast cancer: what is the optimal technique?
por: Chin, Yaw Sinn
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r1or5m887ck3r2p95047c18nfv